Clermont, Florida Correspondent — When a product is heavily marketed and later shown to have contributed to widespread harm, ordinary liability should apply with real force. Shielding companies after the fact weakens deterrence for everybody watching.
Pricing constraints are a separate and more complicated tool. Blunt controls can reduce future development and create shortages.
Stronger liability for misleading marketing and for failure to act on known risk is the cleaner response. Pricing intervention should be narrow and aimed at genuine monopoly situations rather than applied after every crisis as a general punishment.
Dayton, Ohio Correspondent — Liability for deceptive marketing and for ignoring clear danger signals should be robust. That’s different from broad price controls.
The opioid experience showed failures in corporate conduct and in regulatory oversight both, and the second part gets less attention because there’s no defendant.
Strengthening accountability for conduct is justified. Sweeping pricing rules are hard to design without damage somewhere in the supply.
Orange County, California Correspondent — Stronger liability for misleading promotion and withheld risk information is appropriate.
Broad pricing mandates carry their own risk to future supply, and I’d add a financial observation. The litigation itself is becoming the pricing mechanism, in a disorderly way. A company facing an unbounded liability estimate restructures, and the assets end up somewhere with a different name and a cleaner balance sheet.
If we want conduct punished, the vehicle has to survive long enough to pay.
Gastonia, North Carolina Correspondent — If companies pushed product while downplaying known risk, they should face real liability. That’s straightforward and I don’t think it’s actually contested by anyone serious.
Price controls are a different argument wearing the same coat.
What I’d resist is the move where a legitimate finding about conduct gets used to license an unrelated policy that was already on somebody’s list.
Knoxville, Tennessee Correspondent — If you marketed a pain product like a sales territory while the funerals were already loud, you should face liability that changes the next board meeting.
That isn’t the same as a price board that empties the generic cabinet at a rural hospital, and those hospitals are already running on nothing.
Stronger liability where concealment or reckless promotion can be shown. Pricing constraints that are really a political discount will arrive as shortages, and I’ve watched a shortage from the county side.
Conduct and shelf. Keep those words apart and you can do justice without theater.
Long Island, New York Correspondent — Torts exist to make hidden risk expensive. When the risk was hidden, raise the expense.
When the complaint is only that a product is profitable, you’re in a different file entirely, and that file ends in a shortage.
I’ll support discovery that’s real and settlements that aren’t a rounding error against revenue. I won’t support a regime that treats every successful molecule as a crisis in waiting.
I’d also say, from the court side, that mass tort resolution is genuinely difficult and the current vehicles for it are not working well for claimants. That’s worth more attention than it gets.
Cheyenne, Wyoming Correspondent — Lie about the risk, pay.
Price-control the whole cabinet, watch the cabinet thin.
Two sentences. Most hearing rooms want one, and one sentence gets you either immunity or empty shelves.
Jacksonville, Florida Correspondent — Ports moved the precursor and the finished vial, so we see both ends of this business.
Punish the promotion that continued past the deaths. Don’t punish the existence of a margin on a drug that still has to be manufactured by somebody.
Liability for conduct. Contracts and competition for price. Mix them into a single slogan and you get a press conference and a hole in the formulary.
